tradingkey.logo

Nexalin Technology Inc

NXLIW
0.014USD
0.000
Close 11/04, 16:00ETQuotes delayed by 15 min
0.00Market Cap
--P/E TTM

Nexalin Technology Inc

0.014
0.000

More Details of Nexalin Technology Inc Company

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Nexalin Technology Inc Info

Ticker SymbolNXLIW
Company nameNexalin Technology Inc
IPO dateSep 16, 2022
CEOMr. Mark White
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address1776 Yorktown
CityHOUSTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code77056
Phone18322600222
Websitehttps://nexalin.com
Ticker SymbolNXLIW
IPO dateSep 16, 2022
CEOMr. Mark White

Company Executives of Nexalin Technology Inc

Name
Name/Position
Position
Shareholding
Change
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
--
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
--
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
--
--
Mr. Justin Van Fleet
Mr. Justin Van Fleet
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
--
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
--
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--

Revenue Breakdown

No Data
No Data
By Business
By Region
No Data

Shareholding Stats

Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%

Institutional Shareholding

No Data
Reporting Period
No. of institutions
Shares Held
Proportion
Change
No Data

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
No Data

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI